长期艾沙康唑治疗期间血药浓度序列监测
该研究对19例接受艾沙康唑治疗的患者进行血药浓度监测,共分析264份血样。治疗前30天中位浓度为3.69 mg/L,浓度随治疗天数线性增加;治疗时长与更高浓度相关,GGT升高与更低浓度相关。胃肠道不良事件见于6例(31.6%),毒性阈值分别为4.87 mg/L和5.13 mg/L。
要点
- 艾沙康唑血药浓度随治疗天数线性上升,长期用药需监测浓度。
- GGT升高与艾沙康唑浓度降低相关,提示肝功能影响药物暴露。
- 胃肠道不良事件与长疗程和高血药浓度相关,毒性阈值约4.87–5.13 mg/L。
核心结论
- 艾沙康唑有效且耐受性良好,副作用主要为胃肠道反应,与长疗程和高血清浓度相关。
研究设计与样本
- 2017年1月至2018年5月,对接受艾沙康唑治疗的患者进行血药浓度监测,共分析19例患者的264份血样。
主要发现
- 治疗前30天中位艾沙康唑浓度为3.69 mg/L(范围0.64–8.13 mg/L)。
- 治疗每增加一天,浓度线性增加0.032 mg/L(范围0.023–0.041 mg/L),P=0.002。
- 多变量分析显示治疗时长与更高浓度相关(P<0.001),GGT升高与更低浓度相关(P=0.001)。
- 6例患者(31.6%)报告不良事件,主要为胃肠道反应。
关键数值与推荐
- 基于时间依赖ROC曲线,毒性阈值为4.87 mg/L;基于固定时间ROC曲线,毒性阈值为5.13 mg/L。
临床怎么用
- 长期使用艾沙康唑时应考虑监测血药浓度,尤其关注胃肠道不良反应和高浓度风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Isavuconazole is the newest triazole antifungal approved for the treatment of invasive aspergillosis (IA) and invasive mucormycosis in adult patients. OBJECTIVES: To characterize the assessment of the blood levels of isavuconazole and their association with efficacy and toxicity. METHODS: From January 2017 to May 2018, blood samples obtained from patients receiving isavuconazole were analysed for therapeutic drug monitoring. Factors influencing the blood concentrations of isavuconazole, such as weight, length of treatment, route of administration and results of selected liver function tests, were analysed in univariate and multivariate models. The receiver operating characteristic (ROC) curve was analysed to detect the best cut-off for isavuconazole toxicity. RESULTS: A total of 264 isavuconazole blood concentrations in 19 patients were analysed. The median value of isavuconazole concentration in all patients during the first 30 days of therapy was 3.69 mg/L (range 0.64-8.13 mg/L). A linear increase of 0.032 mg/L (range 0.023-0.041 mg/L) for each day of treatment (P = 0.002) was observed. In multivariate analysis the association between the length of treatment and higher levels of isavuconazole (P < 0.001) and higher serum GGT and lower isavuconazole levels (P = 0.001) was confirmed. Adverse events, mainly gastrointestinal, were reported in six patients (31.6%). Based on time-dependent and fixed-time ROC curve analysis, 4.87 mg/L and 5.13 mg/L, respectively, were the identified thresholds for toxicity. CONCLUSIONS: Isavuconazole was efficacious and well tolerated. Side effects, mainly gastrointestinal, were associated with prolonged administration and high serum levels.
引用
- Furfaro E, Signori A, Di Grazia C, et al. Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. J Antimicrob Chemother. 2019. PMID: 31119272. doi:10.1093/jac/dkz188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。